-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

Benzinga·10/22/2026 15:00:05
Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.